PCSK9 and coronary artery disorder: Consistent reductions in LDL-C levels were observed across all subgroups at week 12 and were not mediated by sex, ezetimibe use, baseline PCSK9 levels, statin intensity or presence of coronary artery disease (Additional file 2: Fig. S2).